| Specificity |
This product is specific for Eculizumab |
| Host Species |
Mouse |
| Immunogen |
Eculizumab |
| Conjugate |
Unconjugated |
|
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. |
| Application |
Recommended Usage |
| ELISA |
0.005-1 µg/ml |
| Competitive ELISA |
10-50 µg/ml |
|
| Form |
Lyophilized |
| Storage Buffer |
This product is lyophilized with PBS, pH 7.2, containing 0.02% sodium azide. |
| Reconstitution |
Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/ml. |
| Storage Instructions |
The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles. |
| Purification |
Protein A affinity column |
| Isotype |
Mouse IgG1,κ |
| Clonality |
Monoclonal |
| Clone ID |
13F5 |
| Note |
GenScript can customize this product per customer's request including product size, buffer components, etc. |
Standard curve of Eculizumab Sandwich ELISA. The Eculizumab Sandwich ELISA assay is developed by using Anti-Eculizumab Antibody (4F6), mAb, Mouse (GenScript, A02115-40) and Anti-Eculizumab Antibody (13F5), mAb, Mouse (GenScript, A02116-40) as the capture and detection antibodies, respectively.
In this ELISA assay, Anti-Eculizumab Antibody (13F5), mAb, Mouse (GenScript, A02116-40) was labeled with Biotin.
GenScript can provide customized conjugation services for this product per the customer's request.
The sensitivity of detecting Eculizumab is up to 0.35 ng/ml.
Anti-Eculizumab Antibody (13F5) (GenScript, A02116-40) blocks Eculizumab binding with Human Complement protein C5.
Coating antigen: Eculizumab 1 µg/ml.
Complement protein C5 final concentration: 300 ng/ml.
Anti-Eculizumab antibody dilutions start from 30 μg/ml.
IC50= 1.053 µg/ml.
ELISA binding of Anti-Eculizumab Antibody (13F5), mAb, Mouse (GenScript, A02116-40) with Eculizumab. While the antibody does not recognize the human IgG (data not shown).
Coating antigen: Eculizumab, 1 µg/ml.
Anti-Eculizumab Antibody (13F5), mAb, Mouse (GenScript, A02116-40) dilution start from 1,000 ng/ml.
EC50= 25.09 ng/ml.
| Target Background |
Eculizumab with trade name Soliris, is an FDA-approved drug to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica. Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5. Eculizumab specifically binds to the terminal complement component 5, or C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.Anti-Eculizumab Antibody (13F5), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Eculizumab. |
| Synonyms |
Mouse monoclonal to Eculizumab/Soliris |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
